Tarsus Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
TARS Tarsus Pharmaceuticals Inc
GOVT iShares U.S. Treasury Bond ETF
BAC Bank of America Corp
$NQASPA50JPYN Nasdaq ASPA Industrials Net Total Re
SNP China Petroleum & Chemical Corp
GAEC Gulf Alternative Energy Corp
RDBX Redbox Entertainment Inc
AFG American Financial Group Inc
MRNA Moderna Inc
PFE Pfizer Inc

Health Care : Pharmaceuticals |
Company profile

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. Its lead product candidate, TP-03, is a therapeutic being developed for the treatment of blepharitis caused by the infestation of Demodex mites (Demodex blepharitis). TP-03 is a therapeutic based on the drug, lotilaner, which is designed to paralyze and eradicate mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride (GABA-Cl) channels. The Company is also developing additional clinical-stage product candidates with lotilaner. These include TP-04 for the treatment of rosacea as well as TP-05 for Lyme prophylaxis and community malaria reduction.

Closing Price
Day's Change
-2.70 (-9.75%)
B/A Size
Day's High
Day's Low

10-day average volume:

Here's what legendary investor Bill Miller said in his final investment letter

6:59 am ET October 20, 2021 (MarketWatch)

By Steve Goldstein

Critical information for the trading day

There have been few investors as astute as Bill Miller, the fund manager who famously beat the S&P 500 for 15 years in a row, through to 2005. The value-focused investor's correct calls over the years have ranged from Amazon to bitcoin.

Miller has spent the last 40 years writing investment letters, first alternating every quarter with his late partner, Ernie Kiehne, and then for the last 30 years, writing one himself each period. Miller, chairman and chief investment officer at his own firm Miller Value Partners, now says those duties will go to his son, Bill Miller IV, and Samantha McLemore. Not that he's taking a vow of silence. "If I think there is something interesting or useful to say about the market that others are not saying, I will sit down at the keyboard again," he writes.

Miller's final quarterly missive is, predictably, consistent. "Over the past decade or so my letters have been focused mostly on saying the same thing: we are in a bull market that began in March of 2009 and continues, accompanied by the typical and inevitable pullbacks and corrections. Its end will come either when stocks get too expensive relative to bonds or when earnings decline, neither of which is the case now," he says.

Market timing is foolish -- the stock market has gone up in 70% of postwar years because the U.S. economy grows most of the time. "Most of the returns in stocks are concentrated in sharp bursts beginning in periods of great pessimism or fear, as we saw most recently in the 2020 pandemic decline. We believe time, not timing, is key to building wealth in the stock market," says Miller.

He identifies the current worries, from China's regulatory proclivity to inflation to supply-chain disruptions. "These are legitimate concerns and seem adequately reflected in the market, particularly so when stocks corrected in September. One thing I am pretty confident of is that 12 months from now those worries will have been replaced by a new set of worries," he writes.

But, he says, stocks are entering their strongest seasonal period. "As in most markets, there are areas of overvaluation and of undervaluation, with the bulk of shares appearing to hover in the area of fair value relative to their prospects," he says.

Miller didn't discuss individual stocks. The top holding in the Opportunity Trust that he manages with McLemore is Amazon (AMZN), followed by technology consultant DXC Technology (DXC), Alphabet (GOOGL), software company Splunk (SPLK) and Facebook.

The buzz

Netflix (NFLX) will be in the spotlight after the streaming giant added 4.4 million new paid subscribers in the third quarter, but warned fourth-quarter earnings would be below analyst estimates on the hefty cost of programming.

Wednesday's earnings wave includes Verizon Communications (VZ), and after the close, International Business Machines (IBM) and Tesla (TSLA).

Facebook (FB) will change the name of the company next week, The Verge reported, to align its brand name more toward the "metaverse" that CEO Mark Zuckerberg envisions.

There's a huge day of Fedspeak with five scheduled speeches during the trading day, as well as the release of the Beige Book of economic anecdotes at 2 p.m. Eastern. Chair Jerome Powell will have the last word on Friday before the central bank goes quiet ahead of its next Federal Open Market Committee meeting.

Sens. Joe Manchin and Bernie Sanders are seeking to reach a deal on spending by the end of the week, The Hill reported, citing an unnamed Democratic senator.

Novavax (NVAX) fell in premarket trade on a report from Politico it faces significant hurdles in proving it can manufacture a COVID-19 shot that meets regulators' quality standards.

Listen to the Best New Ideas In Money podcast

The market

After the fifth straight gain for the S&P 500 , U.S. stock futures were steady as the 10-year Treasury yield reached 1.64%.

Bitcoin was trading north of $64,000 on the second day of a U.S. exchange-traded fund tracking cryptocurrency futures.

Random reads

JPMorgan Chase (JPM) CEO Jamie Dimon told the firm's wealth advisers they were getting a raise -- from Windsor Castle.

Georgia is facing an invasion of enormous spiders from Asia.

Need to Know starts early and is updated until the opening bell, but sign up here to get it delivered once to your email box. The emailed version will be sent out at about 7:30 a.m. Eastern.

Want more for the day ahead? Sign up for The Barron's Daily, a morning briefing for investors, including exclusive commentary from Barron's and MarketWatch writers.

-Steve Goldstein


(END) Dow Jones Newswires

October 20, 2021 06:59 ET (10:59 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.